| Autor: |
Alsuliman T; The Faculty of Medicine, Sorbonne University, Paris 75012, France; Department of Hematology and Cellular Therapy, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM, Unité Mixte de Recherche 938, Paris, France. Electronic address: dr.tameem.soliman@gmail.com., Rojas RMM; The Faculty of Medicine, Sorbonne University, Paris 75012, France; Department of Hematology and Cellular Therapy, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM, Unité Mixte de Recherche 938, Paris, France., Basha AA; Hematology and Oncology Department, Saudi German Hospital, Dubai, United Arab Emirates., Musiu P; The Faculty of Medicine, Sorbonne University, Paris 75012, France; Department of Hematology and Cellular Therapy, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM, Unité Mixte de Recherche 938, Paris, France., Magro L; Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, Lille, France., Testi AM; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy., Mohty M; The Faculty of Medicine, Sorbonne University, Paris 75012, France; Department of Hematology and Cellular Therapy, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM, Unité Mixte de Recherche 938, Paris, France. |
| Abstrakt: |
Competing Interests: TA declares consulting fees from Biotest and Amgen; honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Biotest; receiving meeting or travel support from Biotest, Sandoz, Novartis, Astellas Pharma, and Viatris; and leadership or fiduciary roles for the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (unpaid, responsible for practice harmonisation group). MM declares grants or contracts (outside of the present Series papers) from Sanofi, Novartis, and Janssen; consulting fees from Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Jazz, Novartis, Pfizer, Sanofi, Stemline, and Takeda; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Jazz, Novartis, Pfizer, Sanofi, Stemline, Takeda, and MaaT; participation on a Data Safety Monitoring Board or Advisory Board for Janssen; and leadership or fiduciary role for European Society for Blood and Marrow Transplantation and the International Academy for Clinical Hematology. All other authors declare no competing interests. |
